Trial Profile
To evaluate efficacy and safety of dasatinib in unselected elderly (aged > 65 years) chronic myeloid leukemia patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2015
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 03 Aug 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.